HKPD Cellyan Biotechnology Co., Ltd IFRS Annual reports only
Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 2007702 · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY21.7%
TTM net income YoY-102.0%
TTM EPS YoY-101.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin11.9%
Operating margin-11.2%
Net margin-0.1%
FCF margin2.5%
EBITDA margin-10.9%
Returns
ROE-0.6%
ROA-0.3%
ROIC (approx.)-21.0%
Asset turnover2.25x
Leverage & solvency
Liabilities / assets47.0%
Debt / equity0.38x
Current ratio2.99x
Interest coverage-23.39x
Cash quality & payout
Operating cash flow / net income-21.04x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $20.31M | $16.69M | $12.56M |
| Cost of revenue | $17.90M | $13.13M | $9.82M |
| Gross profit | $2.42M | $3.56M | $2.74M |
| SG&A expense | $2.22M | $1.89M | $1.76M |
| Operating income | -$2.28M | -$1.95M | -$1.79M |
| Interest expense | $97,667 | $82,766 | $23,242 |
| Pretax income | $36,112 | $1.53M | $1.02M |
| Income tax | $63,168 | $196,252 | $22,574 |
| Net income | -$27,056 | $1.33M | $998,196 |
| EBITDA | -$2.22M | -$1.90M | -$1.72M |
| EPS (basic) | -0.00 | 0.18 | 0.15 |
| EPS (diluted) | -0.00 | 0.18 | 0.15 |
| Weighted avg. shares (diluted) | 10.21M | 7.37M | 6.84M |
| Banking | |||
| Loans, net | $1.88M | $1.33M | — |
| Balance sheet | |||
| Cash & equivalents | $748,721 | $619,575 | — |
| Short-term investments | $284,546 | $261,877 | — |
| Receivables | $4.66M | $3.70M | — |
| Inventory | $559,982 | $933,299 | — |
| Current assets | $8.73M | $7.80M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $111,245 | $103,242 | — |
| Total assets | $9.42M | $8.67M | — |
| Current liabilities | $2.92M | $3.18M | — |
| Short-term debt | $371,558 | $34,704 | — |
| Long-term debt | $1.50M | $1.12M | — |
| Total debt | $1.88M | $1.15M | — |
| Total liabilities | $4.43M | $4.41M | — |
| Shareholders' equity | $4.99M | $4.25M | $585,242 |
| Net debt | $1.13M | $534,405 | — |
| Cash flow statement | |||
| Operating cash flow | $569,214 | -$394,330 | $1.73M |
| Capital expenditure | $69,916 | $52,736 | $114,643 |
| Free cash flow | $499,298 | -$447,066 | $1.61M |
| Investing cash flow | -$2.45M | -$40,796 | -$132,095 |
| Financing cash flow | $2.00M | $537,315 | -$1.16M |
| Depreciation & amortization | $66,091 | $58,235 | $73,986 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.